Open AccessA careful evaluation of the therapeutic choice is necessary in every phase of diabetes progression
Author(s) -
M. E. Malighetti
Publication year - 2018
Publication title -
aboutopen
Language(s) - English
Resource type - Journals
ISSN - 2465-2628
DOI - 10.19156/abtpn.2018.0061
Subject(s) - medicine , diabetes mellitus , metformin , glycemic , glycated hemoglobin , linagliptin , life expectancy , intensive care medicine , insulin , disease , endocrinology , type 2 diabetes , population , environmental health
National and international diabetes guidelines recommend achieving a target value of glycated hemoglobin value that is dependent upon various factors including patient age, disease duration, co-morbidities, life expectancy and socio-economic conditions. The drug of choice is usually metformin, which can be associated with different classes of oral and injective drugs including insulin, in order to optimize the glycemic balance with the lowest possible risk of hypoglycemic episodes. The clinical case we report shows how a correct therapeutic choice, specifically with linagliptin, can reach a good glycemic control even in elderly subjects, suffering from diabetes mellitus for many years, starting from a severe metabolic imbalance after a multi-year therapy with sulphonylureas (Diabetology).